Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

3.68 

-0.10 -2.7%

as of May 12 '21

52 Week Range:

2.12 6.10


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Nov '19 Dec '20
Equity (BVPS) -2.40
0.90
2.20
1.49
1.14
0.75
0.72
0.65
0.35
1.02
growth rate 100.0% 144.4% -32.3% -23.5% -34.2% -4.0% -9.7% -46.2% 191.4%
Earnings BIT -19.05
-50.53
-63.61
-87.60
-120.00
-110.82
-94.27
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -3.09
-2.56
-2.56
-2.56
-2.56
growth rate 0.0% 0.0% 0.0% 0.0%
ROA -180.62
-85.79
-52.49
-21.47
-46.58
-38.08
-32.10
-43.49
-21.75
-16.76
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -220.68
-134.14
-71.93
-26.86
-76.04
-115.57
-146.87
-309.23
-284.77
-73.53
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -212.66
-93.25
-54.44
-21.92
-57.12
-70.36
-68.73
-74.75
-27.54
-24.52
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 6.69
7.91
8.92
17.28
9.43
1.94
2.72
2.00
3.43
5.45
growth rate 18.2% 12.8% 93.7% -45.4% -79.4% 40.2% -26.5% 71.5% 58.9%
Quick Ratio 6.63
7.83
8.88
17.11
9.28
1.77
2.53
1.63
3.31
5.28
growth rate 18.1% 13.4% 92.7% -45.8% -80.9% 42.9% -35.6% 103.1% 59.5%
Leverage 1.22
1.86
1.24
1.27
2.09
4.44
4.68
76.17
8.64
3.28
growth rate 52.5% -33.3% 2.4% 64.6% 112.4% 5.4% 1,527.6% -88.7% -62.0%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Nov '19 Dec '20
Acct.Receivable 0.16
0.16
8.69
8.38
7.59
15.56
20.09
growth rate 0.0% 5,469.9% -3.6% -9.4% 105.0% 29.1%
Acct.Payable 3.33
5.01
4.08
1.87
14.21
10.00
17.86
50.84
11.41
growth rate 50.2% -18.6% -54.2% 660.9% -29.6% 78.5% 184.7% -77.6%
Cur.Assets 40.59
100.03
70.46
99.94
109.63
183.18
111.21
156.25
261.57
growth rate 146.4% -29.6% 41.8% 9.7% 67.1% -39.3% 40.5% 67.4%
Total Assets 40.99
100.58
89.33
118.61
170.73
245.95
140.99
226.42
328.83
growth rate 145.4% -11.2% 32.8% 43.9% 44.1% -42.7% 60.6% 45.2%
Cash 40.20
99.52
49.76
98.18
88.29
94.95
65.51
153.43
233.35
growth rate 147.6% -50.0% 97.3% -10.1% 7.5% -31.0% 134.2% 52.1%
Inventory 0.20
0.20
0.20
0.17
0.68
0.86
1.40
growth rate 0.0% 0.0% -15.8% 296.5% 26.4% 63.8%
Cur.Liabilities 5.13
11.21
4.08
10.58
56.57
71.44
55.61
45.62
47.96
growth rate 118.4% -63.6% 159.5% 434.7% 26.3% -22.2% -18.0% 5.1%
Liabilities 18.96
19.30
18.80
34.34
87.76
125.45
121.25
153.89
131.84
growth rate 1.8% -2.6% 82.6% 155.6% 42.9% -3.4% 26.9% -14.3%
LT Debt 12.39
7.02
14.00
23.17
26.18
49.27
60.43
82.43
59.04
growth rate -43.4% 99.6% 65.5% 13.0% 88.2% 22.6% 36.4% -28.4%
Equity 22.03
81.28
70.52
56.85
38.50
52.57
1.85
26.22
100.34
growth rate 268.9% -13.2% -19.4% -32.3% 36.6% -96.5% 1,316.3% 282.7%
Common Shares 6.00
8.00
22.00
30.00
36.00
39.00
40.00
42.00
43.00
74.03
72.00
growth rate 33.3% 175.0% 36.4% 20.0% 8.3% 2.6% 5.0% 2.4% 72.2% -2.7%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Nov '19 Dec '20
Capital Expenditures 0.05
0.04
0.28
0.28
6.37
0.65
7.08
2.35
1.93
growth rate -25.9% 607.5% 0.0% 2,150.9% -89.8% 992.9% -66.9% -17.9%
Cash Dividends 0.30
0.30
0.30
2.34
-2.56
6.75
growth rate 0.0% 0.0% 684.0% -100.0% 100.0%
Cash From OA -16.33
-20.38
-45.81
-81.31
-98.85
-94.96
-83.68
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -0.65
-1.08
-1.09
-0.56
-0.73
-1.13
-2.04
-2.60
-1.94
-1.47
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 26.55
90.50
4.09
51.77
36.93
117.53
0.15
84.97
growth rate 240.9% -95.5% 1,167.3% -28.7% 218.3% -99.9% 55,074.7%
FCF -6.00
-15.00
-23.00
-30.00
-16.00
-32.00
-56.00
-91.00
-108.00
-104.00
-91.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Nov '19 Dec '20
Sales 0.86
16.48
17.25
26.88
36.63
45.60
growth rate 1,809.6% 4.6% 55.9% 36.3% 24.5%
Op.Income -27.61
-37.16
-20.65
-50.53
-63.61
-87.60
-120.00
-110.82
-94.27
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -27.61
-37.16
-20.39
-53.88
-71.29
-97.51
-130.80
-101.66
-102.85
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -27.61
-37.16
-20.39
-48.43
-55.10
-66.88
-84.15
-39.96
-46.53
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -1.69
-5.51
-1.27
-1.22
-0.56
-1.24
-1.38
-1.61
-1.94
-0.73
-0.65
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 0.86
4.99
13.59
20.76
26.10
31.01
growth rate 477.6% 172.6% 52.8% 25.7% 18.8%
R&D 17.47
25.68
10.24
29.81
35.13
52.49
87.38
81.33
64.11
growth rate 47.0% -60.1% 191.1% 17.9% 49.4% 66.5% -6.9% -21.2%

Quarterly Statements

Item Name Nov '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT -30.38
-21.53
-25.40
-23.04
-24.30
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Nov '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 15.56
17.56
12.11
16.59
20.09
growth rate 12.9% -31.1% 37.0% 21.1%
Acct.Payable 50.84
8.34
10.70
11.43
11.41
growth rate -83.6% 28.2% 6.8% -0.2%
Cur.Assets 156.25
158.80
199.80
237.74
261.57
growth rate 1.6% 25.8% 19.0% 10.0%
Total Assets 226.42
228.76
268.57
295.88
328.83
growth rate 1.0% 17.4% 10.2% 11.1%
Cash 153.43
135.94
183.28
218.39
233.35
growth rate -11.4% 34.8% 19.2% 6.9%
Inventory 0.86
0.77
1.21
1.05
1.40
growth rate -10.3% 57.2% -13.0% 33.5%
Cur.Liabilities 45.62
51.73
56.97
37.28
47.96
growth rate 13.4% 10.1% -34.6% 28.6%
Liabilities 153.89
153.47
151.72
119.73
131.84
growth rate -0.3% -1.2% -21.1% 10.1%
LT Debt 82.43
76.01
69.45
57.60
59.04
growth rate -7.8% -8.6% -17.1% 2.5%
Equity 26.22
37.23
60.47
97.11
100.34
growth rate 42.0% 62.5% 60.6% 3.3%
Common Shares 74.03
0.08
0.09
0.09
0.10
growth rate -99.9% 8.9% 9.3% 1.1%
Cash Flow Statement Nov '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures 0.89
0.53
0.56
0.14
0.70
growth rate -40.9% 7.2% -75.5% 405.8%
Cash Dividends -0.79
1.21
1.58
1.72
2.25
growth rate 100.0% 31.0% 8.7% 30.6%
Cash From OA -25.05
-21.89
-17.41
-23.89
-20.49
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 23.10
-15.64
22.43
82.92
growth rate -100.0% 100.0% 269.7%
FCF -25.94
-22.42
-17.98
-24.03
-21.18
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Nov '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 11.13
12.92
9.46
9.48
13.75
growth rate 16.1% -26.8% 0.2% 45.1%
Op.Income -30.38
-21.53
-25.40
-23.04
-24.30
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -32.96
-24.07
-28.46
-29.96
-20.35
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -15.49
-12.37
-13.31
-15.55
-5.30
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit 7.57
9.11
6.33
6.10
9.47
growth rate 20.3% -30.5% -3.7% 55.3%
R&D 22.27
15.12
17.27
13.76
17.96
growth rate -32.1% 14.3% -20.4% 30.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (20.26)

YOY Growth Grade:

F (1.79)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -2.56 -1.97 -0.55
EPS / Growth 0.0% -1.87 26.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 25.4% 42.1%
Future PE 0.00 0.01 28.05
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.